Document is current
Any future updates will be listed below
-
Authors
Mhamilawa, Lwidiko E. https://orcid.org/0000-0002-3078-362X
Wikström, Sven
Mmbando, Bruno P.
Ngasala, Billy
Mårtensson, Andreas
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03241901 at ClinicalTrials.govDocuments that mention this clinical trial
Parasite clearance, cure rate, post-treatment prophylaxis and safety of standard 3-day versus an extended 6-day treatment of artemether–lumefantrine and a single low-dose primaquine for uncomplicated Plasmodium falciparum malaria in Bagamoyo district, Tanzania: a randomized controlled trial
https://doi.org/10.1186/s12936-020-03287-5
Electrocardiographic safety evaluation of extended artemether-lumefantrine treatment in patients with uncomplicated Plasmodium falciparum malaria in Bagamoyo District, Tanzania
https://doi.org/10.1186/s12936-020-03309-2
-
Funding
Funding for this research was provided by:
Vetenskapsrådet (Grant number: 2016-0577)
Swedish International Development Agency (Bilateral Sida grant: Bil-Tz 16/9875007059)
Uppsala Universitet
- License Information
-
More Information
Article History
Received: 13 February 2020
Accepted: 26 June 2020
First Online: 14 July 2020
Ethics approval and consent to participate
: The study was conducted in accordance with the Declaration of Helsinki on Good Clinical Practice and received ethical clearance from the National Institute for Medical Research (NIMR/HQ/R.8a/Vol.IX/2477) and Muhimbili University of Health and Allied Sciences, Tanzania, (MU/DRP/ERP/Vol.IX/174) and the Regional Ethical Review Board, Stockholm, Sweden. Written informed consent and ascent was provided by all study participants, in case of children under 7 years, a proxy consent from a parent/legal guardian was obtained. The study is registered at clinicaltrials.gov (identifier: NCT03241901).
: Not applicable.
: The authors declare that they have no competing interests.
